The rs619586 polymorphism has been shown to alter the expression of MALAT1, which act as a competing endogenous RNA (ceRNA) against miR-145. And miR-145 was found to target COL5A1, the interaction between which was shown to be involved in the pathogenesis of invasive meningioma. In this study, we aimed to explore the effect of rs619586 polymorphism and its underlying molecular mechanism in invasive meningioma. Real-time PCR and Western Blot analysis were used to study the differentiated expression of miR-145, MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) and COL5A1 (collagen alpha-1(V) chain) in tumour/serum samples genotyped as rs619586 AA, AG and GG. Computational analysis and luciferase reporter assay were also conducted to identify the regulatory relationship between miR-145 and MALAT1/COL5A1. Meanwhile, expression of miR-145 and COL5A1 in different cell treatment groups was measured to validate the results obtained from earlier experiments. As shown by the results and in tumour/serum samples genotyped as AA, AG and GG, the expression of both MALAT1 and COL5A1 was down-regulated in a stepwise fashion, while the expression of miR-145 was increased, suggesting a potential negative relationship between MALAT1/COL5A1 and miR-145. Meanwhile, miR-145 was shown to bind to MALAT1, while COL5A1 was identified as a virtual target gene of miR-145. As a consequence, a MALAT1/miR-145/COL5A1 molecular pathway was established based on the above results. In particular, with the presence of rs619586 A>G polymorphism, the expression of MALAT1 and COL5A1 was both reduced, leading to reduced invasiveness of meningioma.
Keywords: COL5A1; MALAT1; MiR-145; Rs619586; meningioma; polymorphism.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.